Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950228 | 0.89 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9951344 | 0.85 | HCRTR2 (0.33) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950961 | 0.84 | HCRTR2 (0.57) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9951485 | 0.83 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL10189120 | 0.81 | HCRTR2 (0.59) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950683 | 0.78 | HCRTR2 (0.61) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950358 | 0.76 | OPRK1 (0.32) | — | |
| SCHEMBL9950544 | 0.76 | HCRTR2 (0.56) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950988 | 0.75 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950392 | 0.75 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | claimed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR2 1/4885HCRTR1 2/4885KCNH2 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.